MÃ¼ller Christa E相关文献与解析，生知库

Bidirectional Effect of Long-Term Î(9)-Tetrahydrocannabinol Treatment on mTOR Activity and Metabolome.

长期使用 α”(9)-四氢大麻酚治疗对 mTOR 活性和代谢组的双向影响

期刊:ACS Pharmacology and Translational Science

Bilkei-Gorzo Andras, Schurmann Britta, Schneider Marion, Kraemer Michael, Nidadavolu Prakash, Beins Eva C, MÃ¼ller Christa E, Dvir-Ginzberg Mona, Zimmer Andreas

Crystal structure of adenosine A(2A) receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction.

腺苷 A(2A) 受体与临床候选药物 Etrumadenant 复合物的晶体结构揭示了前所未有的拮抗剂相互作用

期刊:Communications Chemistry

影响因子:6.2

doi:10.1038/s42004-023-00894-6

Claff Tobias, Schlegel Jonathan G, Voss Jan H, VaaÃen Victoria J, WeiÃe Renato H, Cheng Robert K Y, Markovic-Mueller Sandra, Bucher Denis, StrÃ¤ter Norbert, MÃ¼ller Christa E

Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A(2A) Receptor with Preladenant Conjugates.

单个稳定点突变可实现腺苷 A(2A) 受体与前腺苷缀合物的高分辨率共晶结构

期刊:Angewandte Chemie-International Edition

影响因子:16.9

doi:10.1002/anie.202115545

Claff Tobias, Klapschinski Tim A, Tiruttani Subhramanyam Udaya K, VaaÃen Victoria J, Schlegel Jonathan G, Vielmuth Christin, VoÃ Jan H, Labahn JÃ¶rg, MÃ¼ller Christa E

信号转导

发表日期：2022

文献求助收藏

Synthesis and properties of a new water-soluble prodrug of the adenosine A 2A receptor antagonist MSX-2.

腺苷 A 2A 受体拮抗剂 MSX-2 新型水溶性前药的合成及性质

期刊:Molecules

影响因子:4.6

doi:10.3390/molecules13020348

Vollmann Karl, Qurishi Ramatullah, Hockemeyer JÃ¶rg, MÃ¼ller Christa E

Lipopolysaccharide-Neutralizing Peptide Modulates P2X7 Receptor-Mediated Interleukin-1Î² Release.

脂多糖中和肽调节 P2X7 受体介导的白细胞介素-1β 释放

Bidirectional Effect of Long-Term Î(9)-Tetrahydrocannabinol Treatment on mTOR Activity and Metabolome.

长期使用 α”(9)-四氢大麻酚治疗对 mTOR 活性和代谢组的双向影响

Crystal structure of adenosine A(2A) receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction.

腺苷 A(2A) 受体与临床候选药物 Etrumadenant 复合物的晶体结构揭示了前所未有的拮抗剂相互作用

Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A(2A) Receptor with Preladenant Conjugates.

单个稳定点突变可实现腺苷 A(2A) 受体与前腺苷缀合物的高分辨率共晶结构

Synthesis and properties of a new water-soluble prodrug of the adenosine A 2A receptor antagonist MSX-2.

腺苷 A 2A 受体拮抗剂 MSX-2 新型水溶性前药的合成及性质

Lipopolysaccharide-Neutralizing Peptide Modulates P2X7 Receptor-Mediated Interleukin-1Î² Release.

脂多糖中和肽调节 P2X7 受体介导的白细胞介素-1β 释放

Bidirectional Effect of Long-Term Î(9)-Tetrahydrocannabinol Treatment on mTOR Activity and Metabolome.

长期使用 α”(9)-四氢大麻酚治疗对 mTOR 活性和代谢组的双向影响

Crystal structure of adenosine A(2A) receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction.

腺苷 A(2A) 受体与临床候选药物 Etrumadenant 复合物的晶体结构揭示了前所未有的拮抗剂相互作用

Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A(2A) Receptor with Preladenant Conjugates.

单个稳定点突变可实现腺苷 A(2A) 受体与前腺苷缀合物的高分辨率共晶结构

Synthesis and properties of a new water-soluble prodrug of the adenosine A 2A receptor antagonist MSX-2.

腺苷 A 2A 受体拮抗剂 MSX-2 新型水溶性前药的合成及性质

Bidirectional Effect of Long-Term Î(9)-Tetrahydrocannabinol Treatment on mTOR Activity and Metabolome.